Vor Biopharma, Inc. (VOR)
NASDAQ:VOR
Want to see VOR full AI Analyst Report?
VOR Stock Chart & Stats
$16.59
<$0.01(<0.01%)
At close: 4:00 PM EST
$16.59
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$3.62 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)791.09K
Market Cap
$704.42M
Enterprise Value-$64.33M
Total Cash (Recent Filing)$491.52M
Total Debt (Recent Filing)$2.94M
Price to Earnings (P/E)―
Beta4.68
Next Earnings
Aug 06, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-575.83
Shares Outstanding54,185,880
10 Day Avg. Volume670,365
30 Day Avg. Volume791,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.30K
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$33.80Price Target Upside103.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery low reported debt limits interest burden and reduces short-term solvency risk for a pre-revenue biotech. This durable structural strength gives management more runway flexibility to prioritize clinical programs without heavy fixed financing costs, improving strategic optionality.
Regulatory Validation In ChinaConditional approval of telitacicept in China validates the BAFF/APRIL mechanism and establishes a commercial footprint and precedent for multiple indications. This structural regulatory milestone strengthens global program credibility and supports partner/commercial opportunities beyond trial data.
Secured $75M FinancingThe $75M private placement materially extends near-term cash runway to advance global Phase 3 autoimmune programs. Durable impact: reduces immediate refinancing urgency, enables clinical milestones that can de-risk programs and attract future partners or non-dilutive capital if trials progress.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates ongoing runway reliance on external capital. Over months this structural cash burn increases financing frequency risk, pressures strategic choices, and can force dilutive raises that affect long-term shareholder value and program pacing.
Negative Shareholders' EquityNegative equity reflects accumulated losses and reduces the firm's financial buffer, constraining borrowing capacity and increasing creditor/partner scrutiny. This structural weakness limits flexibility for partnerships, licensing deals, or downside protection during protracted clinical development.
Pre-revenue With Widening LossesAbsence of commercial revenue combined with rapidly widening net losses signals long lead time to profitability. Structurally, this raises execution risk: continued heavy R&D and SG&A outlays must translate into successful trials and commercialization before the company achieves sustainable margins.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $3.62 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $704.42M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on May 07, 2026. The company reported -$5.11 earnings per share for the quarter, missing the consensus estimate of -$0.781 by -$4.329.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate is -0.7.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 54,185,880 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of -$5.11 in its last earnings report, missing expectations of -$0.781. Following the earnings report the stock price went up 1.132%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.80 (103.74% Upside)
$33.80 (103.74% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $49.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
197.89%
12-Months-Change
Fundamentals
Return on Equity
87.31%
Trailing 12-Months
Asset Growth
363.58%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$33.80
▲(103.74% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
8.32% Insiders
6.21% Mutual Funds
57.07% Other Institutional Investors
23.53% Public Companies and
Individual Investors